(VIANEWS) – Shares of AB SCIENCE (CAC 40: AB.PA) jumped by a staggering 10.39% to €4.84 at 11:38 EST on Wednesday, following the last session’s upward trend. CAC 40 is jumping 0.56% to €7,331.76, after two consecutive sessions in a row of gains. This seems, as yet, a somewhat positive trend trading session today.
AB SCIENCE’s last close was €4.38, 58.09% under its 52-week high of €10.45.
About AB SCIENCE
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, AB SCIENCE has a trailing twelve months EPS of €-0.28.
Moving Average
AB SCIENCE’s worth is under its 50-day moving average of €5.33 and way below its 200-day moving average of €6.87.
More news about AB SCIENCE (AB.PA).
